NH stock is moving higher on January 28, 2020, after the company announced new business from a 200,000 plus health care provider.
NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced its partnership with The Health Plan, a clinically driven, technology-enhanced and customer-focused health maintenance organization, to increase operating efficiency, lower costs and improve provider satisfaction via the full suite of NaviNet® Open Multi-Payer Portal applications.
The Health Plan is one of the largest locally managed care organizations in West Virginia and Ohio, serving over 200,000 covered lives, and is committed to providing high quality, comprehensive and cost-effective healthcare to members.
NaviNet Open is a leading payor-provider collaboration platform, enhancing communication between health plans and providers to increase operating efficiency, lower costs, improve provider satisfaction and enable expansion. As organizations develop more value-based product lines to support the transition to value-based care, provider alignment and actionable data prior to care delivery becomes critical. To enable these capabilities, health plans and providers need a flexible, extensible infrastructure that fosters collaboration and encourages interoperability. NaviNet Open delivers vital administrative and clinical information to providers in real-time, so they can quickly and easily communicate across multiple health plans.
“NantHealth’s NaviNet Open delivers an easy-to-use full-service application capable of reducing customer service calls and manual processes,” said Jason Landers, Senior Vice President Provider Delivery Services, The Health Plan. “Considering that 85% of our provider networks are active NaviNet Open users, we’ll immediately have the ability to securely and quickly obtain both clinical and administrative functions, with minimal provider adoption effort. This alone is a huge differentiator for us, and we’re projecting a positive ROI in the first year of usage.”
Under terms of the partnership, NaviNet Open will drive The Health Plan’s provider engagement strategy through the NaviNet Open portal, comprised of Eligibility and Benefits, Claims Status Inquiry, Claims Management, Authorizations, Referrals and Document Exchange. The portal will enhance communications by building trust, boosting provider satisfaction, and more closely aligning to value-based outcomes.
“We’re excited to be working in partnership with The Health Plan to enable a direct connection with their provider networks with an outcome of impressive cost savings, ongoing support, product improvements, and enhanced communications,” said Mark Mozley, Senior Vice President, Global Sales & Marketing, NantHealth. “NaviNet Open will continue to drive towards The Health Plan’s overarching goals to achieve instant ROI with decreased administrative costs and an improved provider network collaboration.”
NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®).
On January 27, 2020, NantHealth, Inc. (NASDAQ: NH) presented a novel artificial intelligence platform for aiding pathologists in image-based lung cancer subtyping at the Society for Imaging Science and Technology’s International Symposium on Electronic Imaging 2020. This novel machine vision software platform accurately subtypes lung cancer pathology and achieves high concordance with analysis performed by trained medical pathologists.
An initial report of the AI technology was presented at the Sixth American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) International Joint Conference. The study entitled, “Tumor-infiltrating lymphocytes (TILs) found elevated in lung adenocarcinomas (LUAD) using automated digital pathology masks derived from deep-learning models” concluded that despite lower overall TMB (tumor mutation burden) and lymphocyte levels, there exists a subset of lung cancers with very high infiltrating lymphocyte counts.
Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.
“Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost,” explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth. “Our goal was to develop a scalable remote cloud-based diagnostic imaging system, a NORAD of pathology diagnosis so to speak. To accomplish this, machine vision of digitally transmitted images of tumor tissue would facilitate a scalable cloud-based infrastructure, with an image patch-based, automated system to classify cancers by their immune status.”
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, which is further classified as 40 percent adenocarcinoma (Adeno), 30 percent squamous cell carcinoma (Squamous) and the remainder, large cell carcinoma1. As analyses show that lung adenocarcinomas (LUAD) receive slightly more survival benefit from anti-PD1 therapy than squamous-cell lung carcinomas (LUSC), which have a higher TMB, a team of researchers explored whether lymphocyte distribution in the tumor microenvironment may give a rational explanation for the different responses to immuno-oncology agents independent of TMB.
“By focusing on classifying regions detected as tumorous, we achieved identification of adenocarcinomas versus squamous cell carcinomas in non-small-cell lung cancers with an approximate accuracy rate of 86 percent,” explained Soon-Shiong. “With highly accurate tumor-region and lymphocyte detection, oncologists may better treat their patients with adeno versus squamous-based therapies and the use of immunotherapies may result in better outcomes.”
The system was trained and tested on 876 subtyped NSCLC gigapixel-resolution diagnostic whole slide images (WSI) from 805 patients obtained from The Cancer Genome Atlas (TCGA) sources. Samples were randomly split into training (711 WSIs from 664 patients) and testing (165 WSIs from 141 patients) sets.
Findings show that NantOmics and NantHealth’s fully-automated histopathology subtyping AI method outperforms other algorithms reported in literature for diagnostic WSIs. The system also generated maps of (tumor) regions-of-interest within WSIs, providing novel spatial information on tumor organization.
On January 25, 2020, NantHealth, Inc. (NASDAQ: NH) announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).
The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.
NantHealth’s presentation utilized data on whole exome (WES) DNA tumor and paired germline and matched deep whole transcriptomic sequencing (RNA-Seq) to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification (consensus molecular subtype in CRC). This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.
“Our analysis shows that conventional testing methods may miss potentially actionable HER2 signaling in CRC patients,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “The significant difference suggests that up to 40% more patients may be eligible for HER2 directed therapies, which has implications for drug development and clinical trials.”
To get these stocks much faster (real-time) with alerts, check out the tool we use here. There’s nothing like it on the market.